Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.

November 6, 2026 updated by: Mina Maher, Minia University

Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft. A Comparative Randomized Bi-centric Study

On pump coronary revascularization is a very common leading cause for post-operative cognitive dysfunction regarding patient age grouping and diffuse systemic inflammatory response induced by bypass machine . Many factors are incriminated as pre-operative sleep disturbance, previous history of neurocognitive dysfunction. The accumulating evidence refers to an incidence between 20-40% with majority among geriatric population. The primary pathology is still elusive and many trials are under evaluation. Neuro-inflammation, hypo perfusion, fat emboli and reperfusion injury are among the most postulative aetiologias. The corner stone in the pathology of postoperative cognitive dysfunction is abnormal sleep rhythm. Intra-nasal insulin can provide neuroprotection via providing insulin growth factor and obtund neuronal apoptosis , while dexmedetomidine can antagonize neural-degeneration via regulation of systematic inflammatory cytokines including interleukin 1β, tumor necrosis factor-α, and NF-κB, inhibiting the expressions of Toll-like receptor , and through α2 adrenoceptor-mediated anti-inflammatory pathways

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Al Fayyum, Egypt
        • Fayoum university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult population, 60 years or above, both sex, candidate for elective on pump coronary revascularization

Exclusion Criteria:

  • patient refusal
  • combined reperfusion and valve replacement operations.
  • Emergency or redo CABG.
  • preoperative MMSE score less than 20
  • preoperative cardiomyopathy (ejection fraction <40%).
  • previous history of cerebrovascular stroke or carotid endarterectomy, dementia, language, hearing or visual impairment precluding accurate neurocognitive assessment.
  • history of heparin resistance.
  • chronic use of hypnotics (>3 times weekly for >4 weeks), mood stabilizing drugs (lithium, Na valoprate, anticonvulsants) or melatonin.
  • pre-operative pacing.
  • recent nasal surgery (<3 months), prior maxillofacial trauma with nasal deformity, nasal polyposis or severe allergic rhinitis.
  • severe obstructive sleep apnea (apnea hypopnea index >30), central sleep apnea or obesity-hypoventilation syndrome, and planned postoperative non-invasive ventilation.
  • Chronic acholic population Alcohol Use Disorders Identification Test (AUDIT) score ≥8 for men or ≥7 for women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group

0.5 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)

Active Comparator: Dexmedetomidine group

1.5 mic/kg on 0.5 ml saline 0.9% at 9 PM at night of surgery and 30 minutes before anesthesia induction

Active Comparator: Insulin group

20 IU of regular insulin on 0.5ml ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mini mental state examination
Time Frame: PREOPERATIVE, 1,3,5, 7 days , on hospital discharge

Acute cognitive assessment, score from 0-10 = severe sementia, 10-20 = moderate dementia, 20-25= mild , 25-30= questionably significabt

PREOPERATIVE, 1,3,5, 7 days , on hospital discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
procedure related complication
Time Frame: 3 days

bradycardia, spasm, cough,

3 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Richards-Campbell Sleep Questionnaire
Time Frame: DAILY ( EARLY MORNING at 8-9 AM ) THROUHGOUT ICU stay (10 DAYS)

sleep quality . The counting method was recorded with numbers (0 points to 100 points). The higher the score, the higher the sleep quality star.

DAILY ( EARLY MORNING at 8-9 AM ) THROUHGOUT ICU stay (10 DAYS)
Confusion assessment method - ICU
Time Frame: TWICE DAILY UNTIL ICU DISCHARGE ( 10 DAYS)

POST PERATIVE DELERIUM. CAM (yes or no) includes four aspects: (1) acute onset and fluctuat- ing course, (2) inattention, (3) incoherent thinking, and (4) altered consciousness; the presence of both

(1) and (2), and one of (3) or (4) is diagnostic of POD

With a total score of 30, a higher score indicates a lower incidence of neurocognitive dysfunction

TWICE DAILY UNTIL ICU DISCHARGE ( 10 DAYS)
Montreal cognitive assessment
Time Frame: 7 days

26-30 Normal screening range 18-25 Possible mild cognitive impairment 10-17 Possible moderate cognitive impairment 0-9 Possible severe cognitive impairment

7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 27, 2024

Primary Completion (Actual)

May 14, 2026

Study Completion (Actual)

May 15, 2026

Study Registration Dates

First Submitted

December 14, 2024

First Submitted That Met QC Criteria

December 18, 2024

First Posted (Actual)

December 19, 2024

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 640/R

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.